Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Brad Bernstein, managing director at UBS Private Wealth Management breaks down the state of the U.S. economy and what to expect from Fed policy from the rest of the year.
SpaceX Investor Chad Anderson discusses Starship's latest test flight, what's next, and why he thinks Elon Musk's leadership sent the company in the right direction.
Dilip Rao, CEO of Sharebite, explains how his startup wants to normalize companies feeding their workers, the role of the private sector in public concerns, and more.
Athlete compensation, player unions and realignment dominate discussions — everything in college sports is open for discussion, interpretation and adjustment.
Sola Mahfouz and Malaina Kapoor, authors of 'Defiant Dreams: The Journey of an Afghan Girl Who Risked Everything for Education' discuss how Sola overcame the Taliban to get an education.
